Affiliation: Medical University of Vienna
- Allergy testing: the role of recombinant allergensNadine Mothes
Zentrum für Physiologie und Pathophysiologie, Institut fur Pathophysiologie, Abteilung Immunpathologie, Medizinische Universität Wien, Vienna, Austria
Clin Chem Lab Med 44:125-32. 2006..Besides their diagnostic application, recombinant allergens and hypoallergenic derivatives thereof have also been used as vaccines in clinical trials, and recent results have shown their usefulness for the treatment of type I allergy...
- Transition from a botanical to a molecular classification in tree pollen allergy: implications for diagnosis and therapyNadine Mothes
Center for Physiology and Pathophysiology, Department of Pathophysiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
Int Arch Allergy Immunol 135:357-73. 2004..Information obtained by diagnostic testing with marker allergens will be important for the appropriate selection of patients for allergen-specific forms of therapy...
- Tree pollen allergensNadine Mothes
University of Vienna, Vienna Medical School, Vienna, Austria
Clin Allergy Immunol 18:165-84. 2004
- Autoimmunity and atopic dermatitisIrene Mittermann
Department of Pathophysiology, Division of Immunopathology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
Curr Opin Allergy Clin Immunol 4:367-71. 2004..This review summarizes evidence for autoimmune mechanisms in atopic dermatitis and suggests novel pathomechanisms that may be involved in this disease...
- Biology of tree pollen allergensNadine Mothes
Division of Immunopathology, Department of Pathophysiology, Vienna General Hospital, AKH, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
Curr Allergy Asthma Rep 4:384-90. 2004..Moreover, we describe novel recombinant allergen-based forms of specific immunotherapy...
- Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergyThierry Batard
Stallergènes, R and D, Antony, France
Int Arch Allergy Immunol 136:239-49. 2005..We describe the production in Escherichia coli as a recombinant protein of clinical grade wild-type Bet v 1a (rBet v 1a), to be used as a candidate vaccine against birch pollen allergy...
- The cradle of IgE autoreactivity in atopic eczema lies in early infancyNadine Mothes
J Allergy Clin Immunol 116:706-9. 2005